EA201100244A1 - NEW EPALRESTATIC CRYSTAL SALTS - Google Patents

NEW EPALRESTATIC CRYSTAL SALTS

Info

Publication number
EA201100244A1
EA201100244A1 EA201100244A EA201100244A EA201100244A1 EA 201100244 A1 EA201100244 A1 EA 201100244A1 EA 201100244 A EA201100244 A EA 201100244A EA 201100244 A EA201100244 A EA 201100244A EA 201100244 A1 EA201100244 A1 EA 201100244A1
Authority
EA
Eurasian Patent Office
Prior art keywords
new crystalline
crystalline salts
new
epalrestatic
prophylaxis
Prior art date
Application number
EA201100244A
Other languages
Russian (ru)
Other versions
EA018600B1 (en
Inventor
Изабель Калофонос
Г. Патрик Стэнли
Вильям Мартин-Дойл
Димитрис Калофонос
Джефри С. Сталтс
Травис Л. Хьюстон
Original Assignee
Бионевия Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бионевия Фармасьютикалс, Инк. filed Critical Бионевия Фармасьютикалс, Инк.
Publication of EA201100244A1 publication Critical patent/EA201100244A1/en
Publication of EA018600B1 publication Critical patent/EA018600B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Изобретение относится к новым кристаллическим солям 5-[(1Z,2Е)-2-метил-3-фенилпропенилиден]-4-оксо-2-тиоксо-3-тиазолидинуксусной кислоты. Представлены способ получения и описание новых кристаллических солей в соответствии с различными вариантами изобретения. Изобретение также относится к фармацевтическим соединениям, содержащим новые кристаллические соли, и с терапевтическим применением новых кристаллических солей для лечения и/или профилактики различных заболеваний, включая лечение и/или профилактику осложнений диабета, ингибирование альдозо-редуктазы, а также создание кардиопротекторного эффекта у пациентов без диабета.The invention relates to new crystalline salts of 5 - [(1Z, 2E) -2-methyl-3-phenylpropenylidene] -4-oxo-2-thioxo-3-thiazolidine acetic acid. Presents a method of obtaining and describing new crystalline salts in accordance with various variants of the invention. The invention also relates to pharmaceutical compounds containing new crystalline salts and with the therapeutic use of new crystalline salts for the treatment and / or prophylaxis of various diseases, including the treatment and / or prophylaxis of diabetes complications, the inhibition of aldose reductase, and the creation of a cardioprotective effect in patients without diabetes.

EA201100244A 2008-07-25 2009-07-24 Novel crystalline salts of epalrestat EA018600B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8361108P 2008-07-25 2008-07-25
PCT/US2009/051687 WO2010011922A2 (en) 2008-07-25 2009-07-24 Novel crystalline salts of epalrestat

Publications (2)

Publication Number Publication Date
EA201100244A1 true EA201100244A1 (en) 2011-08-30
EA018600B1 EA018600B1 (en) 2013-09-30

Family

ID=41570881

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100244A EA018600B1 (en) 2008-07-25 2009-07-24 Novel crystalline salts of epalrestat

Country Status (2)

Country Link
EA (1) EA018600B1 (en)
WO (1) WO2010011922A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697735B2 (en) 2008-07-25 2014-04-15 Bionevia Pharmaceuticals, Inc. Solid forms of epalrestat
PL2326632T3 (en) 2008-09-06 2017-10-31 Bionevia Pharmaceuticals Inc Novel choline cocrystal of epalrestat
ES2555927T3 (en) 2011-01-20 2016-01-11 Bionevia Pharmaceuticals Inc. Compositions of modified release of epalrestat or a derivative thereof and methods for using them
JP6976047B2 (en) * 2015-08-28 2021-12-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 How to prepare epalrestat
CN113336718B (en) * 2021-06-01 2023-02-28 天津大学 Epalrestat-metformin salt and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5740478A (en) * 1980-08-22 1982-03-06 Ono Pharmaceut Co Ltd Rhodanine derivative, its preparation and aldose reductase inhibitor containing rhodanine derivative
EP1106210A3 (en) * 1999-12-07 2003-12-03 Pfizer Products Inc. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
JP4892915B2 (en) * 2005-10-04 2012-03-07 大日本印刷株式会社 Epalrestat manufacturing method

Also Published As

Publication number Publication date
WO2010011922A2 (en) 2010-01-28
WO2010011922A3 (en) 2010-04-22
EA018600B1 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
EA201200489A1 (en) PHARMACEUTICAL COMPOSITION, INCLUDING NEW CHOLINESE EPALRESTATE CRYSTAL
EA201100778A1 (en) HETEROCYCLIC SUBSTITUTED COMPOUNDS AS HIF INHIBITORS
PH12018500768A1 (en) Purin derivatives for use in the treatment of fab-related diseases
EA201071144A1 (en) HETEROCYCLIC DERIVATIVES
EA201100246A1 (en) NEW BETAINE CRYSTAL EPALRESTAT
EA201071045A1 (en) COMPOUNDS OF OXADIAZOANTHRACENE FOR THE TREATMENT OF DIABETES
RU2533217C3 (en) PREPARATION CONTAINING INSULIN, NICOTINAMIDE AND AMINO ACID
EA201290267A1 (en) DERIVATIVES OF DIOXABICICLO [3.2.1] OKTAN-2,3,4-TRIOL
EA200802223A1 (en) 1,5-DIPHENYLPYRAZOLES II AS HSP90 INHIBITORS
UY32032A (en) "2- [1-SUBSTITUTED-1H-PIRAZOLO [3,4-D] PIRIMIDIN-4-IL] (IO, OXI OR AMINO) -N- (HETEROARIL) ALCANAMIDS"
EA200900896A1 (en) HETEROCYCLIC COMPOUND RECEPTOR-AGONISTS (VARIANTS) PHARMACEUTICAL COMPOSITION ON THEIR BASIS METHOD FOR TREATING DIABETES AND METABOLIC DISORDERS, a method of stimulating insulin production (VARIANTS) AND METHODS FOR REDUCING GLUCOSE LEVEL IN BLOOD AND TRIGLYCERIDES BY COMPOUNDS LISTED
EA201270560A1 (en) SPYROPYPERIDINE COMPOUNDS AND THEIR PHARMACEUTICAL APPLICATIONS FOR TREATMENT OF DIABETES
EA201100244A1 (en) NEW EPALRESTATIC CRYSTAL SALTS
EA200970090A1 (en) METABOLISM MODULATORS AND TREATMENT OF RELATED DISORDERS
EA201290078A1 (en) HETEROCYCLIC COMPOUNDS TO INHIBIT PASK
ATE438623T1 (en) AROYL-O-PIPERIDINE DERIVATIVES FOR THE TREATMENT OF PROBLEMS RELATED TO DIABETES
EA201001508A1 (en) BRIDGES HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS
EA201000007A1 (en) Derivatives of indazolamide
EA201270492A1 (en) COMPOUNDS FOR THE TREATMENT OF DISLIPIDEMIC AND RELATED DISEASES
EA201000098A1 (en) HINAZOLINAMIDE DERIVATIVES
WO2011026911A8 (en) Bipyridines useful for the treatment of proliferative diseases
MX2012002758A (en) Pyrazinylpyridines useful for the treatment of proliferative diseases.
NZ587433A (en) Compounds and method for reducing uric acid
EA201100623A1 (en) SULPHOXIMIN-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THEIR OBTAINING AND APPLICATION AS MEDICINES
EA201000362A1 (en) 1,3-DIHYDROIZOINDOL DERIVATIVES

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU